Lama84

The human chronic myeloid leukemia cell line, LAMA84, was obtained by DSMZ (Braunschweig, Germany). The human colorectal adenocarcinoma cell line, SW480, the human lung carcinoma cell line, A549, and the human bone marrow-derived stromal cell line, HS5, were obtained by ATCC (Manassas, VA, USA). LAMA84, SW480 and A549 cell lines were cultured in RPMI 1640 medium (Euroclone, UK), HS5 (Human bone marrow stromal cells) cell line was cultured in DMEM high glucose (Euroclone, UK). Human Umbilical Vein Endothelial Cells (HUVEC) were obtained from Lonza and grown in Endothelial Growth Medium (EGM, Clonetics, Verviers, Belgium). Human peripheral blood mononuclear cells (PBMC) were isolated using Ficoll Paque (GE Helthcare Bio Science, Uppsala, Sweden). Anti-TRAIL neutralizing antibody was from AbCam (Cambridge, UK). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA), if not cited otherwise.

The human chronic myeloid leukemia cell line, LAMA84, was obtained by DSMZ (Braunschweig, Germany) and cultured in RPMI 1640 medium (Euroclone, UK), supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin (Euroclone, UK). SB431542 (Cayman Chemical, Michigan, USA) was solubilized at 10 mM stock solution in DMSO, and stored at -20°C. Working dilutions were prepared in medium. All other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA), if not cited otherwise.

Chronic myeloid leukaemia cell line, LAMA84, was obtained from DSMZ (Braunschweig, Germany); human primary CD34⁺ cells and bone marrow primary stromal cells (BMSCs) were obtained from Lonza (Basel, Switzerland). LAMA84 cells were cultured in RPMI 1640 medium, supplemented with 10% foetal bovine serum (FBS), 2 mM L‐glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (Euroclone, UK). CD34⁺ cells were cultured in IMDM medium, supplemented with 15% FBS, 2 mM L‐glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (Euroclone, UK). BMSCs were cultured in MyeloCult H5100 (STEMCELL Technologies Inc., Vancouver, BC, Canada). Gefitinib or Erlotinib (Cayman Chemical, Ann Arbor, MI, USA) was solubilized at 10‐mM stock solution in DMSO and stored at −20°C. Neutralizing antibody anti‐AREG (R&D Systems, Abingdon, UK) was reconstituted at 0.2 mg/ml in sterile PBS, aliquoted and stored at −20°C. Recombinant Areg (R&D Systems, Abingdon, UK) was reconstituted at 0.1 mg/ml in sterile PBS, aliquoted and stored at −20°C. Working dilutions, where necessary, were prepared in medium. All other reagents were purchased from Sigma‐Aldrich (St. Louis, MO, USA), if not cited otherwise.